Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial

Abstract Background The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD). Methods Thirty (30) intrabony defects of 18 patients (9 males, 9 females) were random...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Boróka Klára Csifó-Nagy, Eleonóra Sólyom, Vera Lili Bognár, Annamária Nevelits, Ferenc Dőri
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Intrabony defects Periodontal healing Advanced platelet-rich fibrin Enamel matrix derivative Dentistry RK1-715
Acceso en línea:	https://doaj.org/article/c484d022c6da4127be8cc0f66bbca832
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c484d022c6da4127be8cc0f66bbca832
record_format	dspace
spelling	oai:doaj.org-article:c484d022c6da4127be8cc0f66bbca8322021-11-21T12:32:16ZEfficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial10.1186/s12903-021-01925-11472-6831https://doaj.org/article/c484d022c6da4127be8cc0f66bbca8322021-11-01T00:00:00Zhttps://doi.org/10.1186/s12903-021-01925-1https://doaj.org/toc/1472-6831Abstract Background The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD). Methods Thirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n = 15) or EMD (control, n = 15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability. Results Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33 ± 1.58 mm in the A-PRF+ group, respectively 2.60 ± 1.18 mm in the EMD group (p < 0.001). Conclusion Within the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD during surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing. Clinical Relevance A-PRF+ may be suitable for the treatment of intrabony periodontal defects. Trial registration number (TRN) NCT04404374 (ClinicalTrials.gov ID).Boróka Klára Csifó-NagyEleonóra SólyomVera Lili BognárAnnamária NevelitsFerenc DőriBMCarticleIntrabony defectsPeriodontal healingAdvanced platelet-rich fibrinEnamel matrix derivativeDentistryRK1-715ENBMC Oral Health, Vol 21, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Intrabony defects Periodontal healing Advanced platelet-rich fibrin Enamel matrix derivative Dentistry RK1-715
spellingShingle	Intrabony defects Periodontal healing Advanced platelet-rich fibrin Enamel matrix derivative Dentistry RK1-715 Boróka Klára Csifó-Nagy Eleonóra Sólyom Vera Lili Bognár Annamária Nevelits Ferenc Dőri Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
description	Abstract Background The aim of the study was to clinically evaluate the healing of intrabony defects after treatment with a new generation of platelet-rich fibrin (A-PRF+) respect to enamel matrix derivative (EMD). Methods Thirty (30) intrabony defects of 18 patients (9 males, 9 females) were randomly treated with A-PRF+ (test, n = 15) or EMD (control, n = 15). The following clinical parameters were recorded at baseline and 6 months after surgery: pocket depth (PD), gingival recession (GR) and clinical attachment level (CAL). After debridement the intrabony defects were filled with A-PRF+ in the test group, respectively with EMD in the control group, and fixed with sutures to ensure wound closure and stability. Results Both treatment methods resulted in statistically significant PD reductions, respectively CAL gains six months post-operatively. No statistically significant differences were found between the two groups as the mean CAL gain was 2.33 ± 1.58 mm in the A-PRF+ group, respectively 2.60 ± 1.18 mm in the EMD group (p < 0.001). Conclusion Within the limits of this study the new-generation platelet-rich fibrin seems to be as clinically effective as EMD during surgical treatment of intrabony defects. Treatment with A-PRF+ or EMD resulted in reliable clinical outcomes. The use of A-PRF+ as a human autologous product can give a positive impact on periodontal healing. Clinical Relevance A-PRF+ may be suitable for the treatment of intrabony periodontal defects. Trial registration number (TRN) NCT04404374 (ClinicalTrials.gov ID).
format	article
author	Boróka Klára Csifó-Nagy Eleonóra Sólyom Vera Lili Bognár Annamária Nevelits Ferenc Dőri
author_facet	Boróka Klára Csifó-Nagy Eleonóra Sólyom Vera Lili Bognár Annamária Nevelits Ferenc Dőri
author_sort	Boróka Klára Csifó-Nagy
title	Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
title_short	Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
title_full	Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
title_fullStr	Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
title_full_unstemmed	Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
title_sort	efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial
publisher	BMC
publishDate	2021
url	https://doaj.org/article/c484d022c6da4127be8cc0f66bbca832
work_keys_str_mv	AT borokaklaracsifonagy efficacyofanewgenerationplateletrichfibrininthetreatmentofperiodontalintrabonydefectsarandomizedclinicaltrial AT eleonorasolyom efficacyofanewgenerationplateletrichfibrininthetreatmentofperiodontalintrabonydefectsarandomizedclinicaltrial AT veralilibognar efficacyofanewgenerationplateletrichfibrininthetreatmentofperiodontalintrabonydefectsarandomizedclinicaltrial AT annamarianevelits efficacyofanewgenerationplateletrichfibrininthetreatmentofperiodontalintrabonydefectsarandomizedclinicaltrial AT ferencdori efficacyofanewgenerationplateletrichfibrininthetreatmentofperiodontalintrabonydefectsarandomizedclinicaltrial
_version_	1718418969490096128

Efficacy of a new-generation platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized clinical trial

Ejemplares similares